FDA Approval: Novartis‘ Exforge HCT combo high-blood pressure pill.
FDA Approval: Medicis‘ Dysport, a Botox competitor. And both end up with black box warnings!
PDI and Novartis end a co-promote agreement.
Pre-merger trading over at Schering? Hmmm…
——
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply